Amplimune
Amplimune
Mycobacterium cell wall fraction (MCWF) immunostimulant,
Description:
Immuno-stimulant, Antibiotic Alternative for Bovine Infectious Disease
Protect your client’s investment without antibiotics
Composition
Amplimune, mycobacterium cell wall fraction (MCWF) immunostimulant, is approved by the USDA for the treatment of bovine infectious disease.
Indications
Amplimune is approved for use as immunotherapeutic treatment for the reduction of clinical signs and mortality associated with enterotoxigenic Escherichia coli (ETEC) K99 diarrhoea and reduction of clinical signs of Mastitis, Endometritis and Metritis
Direction for use:
Amplimune is a low volume, single-dose intravenous (IV) therapy.
Colibacillosis caused by ETEC K99 is one of the principal causes of neonatal calf diarrhea. ETEC infection occurs most frequently in the first week of life, before the calf can become resistant to the disease.
Early treatment of colibacillosis must be directed toward the control of the bacteria in the intestinal tract. Studies indicate that the optimum times at which to administer Amplimune are:
- Early in the disease process, and
- On farms with persistent coli scours, treating all calves immediately, one day after birth.
Studies have shown that a single, 1 mL dose of Amplimune can induce an immediate innate immune response in the neonatal calf to minimize and control the damage caused by pathogenic E. coli. Therefore, the calf’s ability to overcome the disease challenge is greatly enhanced. As an alternative to antibiotics, Amplimune, with or without fluid therapy, is effective against colibacillosis.
The brief description of the medicine is for information purpose only. Read the content of the package leaflet carefully before use. If you have any further questions, ask your veterinarian or pharmacist.